Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	52.65	56.81	70.17	31.16
Short-Term Investments	437.89	248.48	77.31	-
Cash & Short-Term Investments	490.54	305.28	147.48	31.16
Cash Growth	60.69%	107.00%	373.31%	-
Prepaid Expenses	7.82	4.42	1.5	0.11
Restricted Cash	0.11	0.11	0.09	-
Other Current Assets	0.1	-	1.81	-
Total Current Assets	498.56	309.8	150.87	31.27
Property, Plant & Equipment	12.89	4.97	4	0.34
Long-Term Deferred Charges	0.04	-	0.3	-
Other Long-Term Assets	0.95	0.16	0.25	-
Total Assets	512.43	314.93	155.42	31.6
Accounts Payable	4.19	1.95	2.5	1.45
Accrued Expenses	12.1	6.08	5.63	0.21
Current Portion of Leases	2.76	0.74	0.67	-
Total Current Liabilities	19.05	8.77	8.8	1.66
Long-Term Debt	-	-	4.2	10.44
Long-Term Leases	8.73	0.74	1.48	-
Total Liabilities	27.78	9.51	14.48	12.1
Common Stock	0.05	0.04	0	0.03
Additional Paid-In Capital	719.29	429.66	19.8	0.56
Retained Earnings	-235.23	-123.75	-45.44	-10.65
Comprehensive Income & Other	0.55	-0.52	0	-
Total Common Equity	484.65	305.43	-25.63	-10.06
Shareholders' Equity	484.65	305.43	140.94	19.51
Total Liabilities & Equity	512.43	314.93	155.42	31.6
Total Debt	11.48	1.48	6.35	10.44
Net Cash (Debt)	479.06	303.8	141.13	20.72
Net Cash Growth	57.69%	115.26%	581.01%	-
Net Cash Per Share	12.30	14.65	93.73	26.66
Filing Date Shares Outstanding	47.79	36.5	4.17	0.78
Total Common Shares Outstanding	47.77	36.58	4.17	0.78
Working Capital	479.51	301.04	142.07	29.61
Book Value Per Share	10.15	8.35	-6.15	-12.95
Tangible Book Value	484.65	305.43	-25.63	-10.06
Tangible Book Value Per Share	10.15	8.35	-6.15	-12.95
Machinery	4.55	3.78	1.76	0.3
Construction In Progress	0.12	0.43	0.03	0.06
Leasehold Improvements	0.3	0.28	0.26	-

Source: S&P Capital IQ. Standard template. Financial Sources.